Table 1 Univariable MR results of the effect of genetically predicted atherogenic lipid-related traits on COVID-19 risk
Exposure traits | Outcome traits | N of SNVs | IVW method | MR-Egger regression method | Weighted median method | Weighted mode method | Heterogeneity (IVW method) | |
|---|---|---|---|---|---|---|---|---|
OR (95% CI) P-value | OR (95% CI) P-value | Intercept (SE) P-value | OR (95% CI) P-value | OR (95% CI) P-value | Cochran’s Q P-value | |||
Apo-B | COVID-19 susceptibility | 128 | 0.995 (0.93–1.07) 0.89 | 1.013 (0.91–1.12) 0.81 | − 0.0009 (0.0019) 0.64 | 1.057 (0.93–1.19) 0.38 | 1.026 (0.93–1.14) 0.63 | 128.4 0.45 |
Apo-B | COVID-19 hospitalization | 126 | 0.995 (0.85–1.16) 0.94 | 0.909 (0.72–1.15) 0.43 | 0.0040 (0.0041) 0.33 | 0.902 (0.71–1.15) 0.41 | 0.881 (0.68–1.15) 0.35 | 125.7 0.47 |
Apo-B | COVID-19 severity | 130 | 1.033 (0.82–1.31) 0.79 | 0.933 (0.64–1.35) 0.71 | 0.0046 (0.0065) 0.48 | 0.935 (0.67–1.31) 0.70 | 0.979 (0.70–1.36) 0.90 | 172.0 0.007 |
LDL-C | COVID-19 susceptibility | 114 | 1.048 (0.96–1.14) 0.27 | 1.028 (0.89–1.18) 0.70 | 0.0008 (0.0023) 0.74 | 1.056 (0.93–1.20) 0.41 | 1.025 (0.90–1.17) 0.71 | 114.2 0.45 |
LDL-C | COVID-19 hospitalization | 113 | 0.986 (0.83–1.17) 0.86 | 0.853 (0.64–1.14) 0.28 | 0.0057 (0.0046) 0.22 | 0.892 (0.68–1.17) 0.41 | 0.889 (0.67–1.18) 0.42 | 108.5 0.58 |
LDL-C | COVID-19 severity | 115 | 1.034 (0.83–1.29) 0.77 | 0.806 (0.54–1.21) 0.30 | 0.0099 (0.0067) 0.14 | 0.882 (0.62–1.26) 0.49 | 0.949 (0.65–1.38) 0.79 | 127.1 0.19 |
TG | COVID-19 susceptibility | 208 | 1.065 (1.00–1.13) 0.045 | 1.101 (0.99–1.21) 0.052 | − 0.0014 (0.0016) 0.36 | 1.099 (0.99–1.22) 0.07 | 1.079 (0.98–1.19) 0.13 | 235.9 0.08 |
TG | COVID-19 hospitalization | 205 | 1.174 (1.04–1.33) 0.012 | 1.275 (1.06–1.53) 0.010 | − 0.0036 (0.0030) 0.23 | 1.167 (0.96–1.42) 0.12 | 1.201 (1.01–1.43) 0.039 | 192.5 0.71 |
TG | COVID-19 severity | 208 | 1.274 (1.08–1.50) 0.004 | 1.310 (1.03–1.67) 0.030 | − 0.0013 (0.0040) 0.75 | 1.201 (0.92–1.57) 0.18 | 1.160 (0.91–1.47) 0.22 | 210.2 0.43 |